News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Momenta Pharmaceuticals, Inc. (Jobs) Sees Longer US Review for Generic Lovenox
June 28, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, June 28 (Reuters) - Momenta Pharmaceuticals Inc. said on Thursday a U.S. review of its application to sell a generic version of Sanofi-Aventis' big-selling Lovenox blood-thinner is taking longer than it previously projected.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Multiple sclerosis
Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint
May 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
April 30, 2025
·
8 min read
·
BioSpace Editorial Staff
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
April 30, 2025
·
2 min read
·
Tristan Manalac
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
April 29, 2025
·
2 min read
·
Tristan Manalac
